银丹解毒颗粒治疗SARS-CoV-2变异株B.1.1.7 COVID-19临床观察  

Clinical Observation of Yindan Jiedu Granules in Treatment of SARS-CoV-2 Variant B.1.1.7 COVID-19

作　　者：任婕 刘遥[1] 吴秀艳 王宪波[1] REN Jie;LIU Yao;WU Xiuyan;WANG Xianbo(Beijing Ditan Hospital,Capital Medical University,Beijing China 100015;School of Traditional Chinese Medicine,Beijing University of Chinese Medicine,Beijing China 102488)

机构地区：[1]首都医科大学附属北京地坛医院,北京100015 [2]北京中医药大学中医学院,北京102488

出　　处：《中医学报》2022年第2期391-396,共6页Acta Chinese Medicine

基　　金：北京市科学技术委员会“创新品种及平台培育”项目(Z201100005420012)。

摘　　要：目的:观察银丹解毒颗粒治疗SARS-CoV-2变异株B.1.1.7新型冠状病毒肺炎(coronavirus disease 2019,COVID-19)的临床疗效。方法:前瞻性收集2021年1月18日至2月1日北京地坛医院收治的17例服用银丹解毒颗粒的SARS-CoV-2变异株B.1.1.7 COVID-19患者,其中9例患者入院即口服银丹解毒颗粒(观察组Ⅰ),8例患者入院4 d后开始口服银丹解毒颗粒(观察组Ⅱ)。比较两组患者发热、呼吸道症状持续时间、炎症和免疫指标水平、病毒核酸水平及肺部炎症改善情况。结果:观察组Ⅰ咳嗽咳痰持续时间为6.50(4.50,8.50)d,观察组Ⅱ为11.00(10.00,12.50)d,两组比较,差异有统计学意义(P<0.05)。观察组Ⅰ咽部不适持续时间为7.00(6.00,10.00)d,观察组Ⅱ为11.00(10.00,12.50)d,两组比较,差异有统计学意义(P<0.05)。观察组Ⅰ胸闷持续时间为2.50(1.25,6.00)d,观察组Ⅱ为12.50(7.50,14.75)d,两组比较,差异有统计学意义(P<0.05)。观察组Ⅰ发热持续时间为6.00(3.00,7.00)d,观察组Ⅱ为7.00(3.50,7.75)d,两组比较,差异无统计学意义(P>0.05)。观察组Ⅰ肺部炎症渗出性病变消退时间为14.00(10.00,16.00)d,观察组Ⅱ为18.00(16.00,20.25)d,两组比较,差异有统计学意义(P=0.01)。入院第14天,观察组Ⅰ血清淀粉样蛋白A显著低于入院第7天(P=0.001);入院第14天,观察组Ⅱ血清淀粉样蛋白A低于入院第7天(P=0.059)。结论:银丹解毒颗粒同样适用于SARS-CoV-2变异株B.1.1.7 COVID-19患者,及早应用可更好地改善呼吸道症状、促进肺部炎症渗出性病变的吸收。Objective:To investigate the therapeutic effect of Yindan Jiedu Granules on SARS-CoV-2 variant B.1.1.7 COVID-19.Methods:17 SARS-CoV-2 variant B.1.1.7 COVID-19 patients were prospectively enrolled in Beijing Ditan Hospital from January 18 to February 1,2021.Among them,9 patients were treated with Yindan Jiedu Granules(GroupⅠ)immediately after admission,and the other 8 cases were treated with Yindan Jiedu Granules(GroupⅡ)4 days after admission.The duration of fever and respiratory symptoms,inflammation and immune index levels,viral nucleic acid levels,and improvement of lung inflammation were compared between the two groups of patients.Results:The duration of cough and expectoration was 6.50(4.50,8.50)days in GroupⅠ,which was significantly shorter than that in GroupⅡ11.00(10.00,12.50)days(P<0.05).The duration of throat discomfort was 7.00(6.00,10.00)days in GroupⅠ,which was significantly shorter than that in GroupⅡ11.00(10.00,12.50)days(P<0.05).The duration of chest tightness was 2.50(1.25,6.00)days in GroupⅠ,which was shorter than that in GroupⅡ12.50(7.50,14.75)days(P<0.05).The duration of fever was 6.00(3.00,7.00)days in GroupⅠand 7.00(3.50,7.75)days in GroupⅡ,and there was no significant difference between the two groups(P>0.05).The regression time of pulmonary inflammatory exudative lesions in Group I was 14.00(10.00,16.00)days,which was significantly shorter than that in GroupⅡ18.00(16.00,20.25)days(P=0.01).Serum amyloid A(SAA)in GroupⅠwas significantly decreased on the 14 th day of admission compared with the 7 th day(P=0.001),and that in GroupⅡwas also decreased on the 14 th day of admission compared with the 7 th day of admission(P=0.059).Conclusion:Yindan Jiedu Granules are also effective for SARS-CoV-2 variant B.1.1.7 COVID-19 patients.Early application of it could improve respiratory symptoms and promote the absorption of inflammatory exudative lesions in the lung.

关 键 词：新型冠状病毒肺炎 银丹解毒颗粒 SARS-CoV-2变异株B.1.1.7 

分 类 号：R256.1[医药卫生—中医内科学]